Timolol with travoprost ocular
- Drugs List
- Therapeutic Indications
- Dosage
- Contraindications
- Precautions and Warnings
- Pregnancy and Lactation
- Side Effects
- Monograph
Presentation
Eye drops containing timolol and travoprost.
Drugs List
Therapeutic Indications
Uses
Elevated IOP in ocular hypertension when single agent insufficient
Elevated IOP in open-angle glaucoma when single agent insufficient
Dosage
Adults
Instil 1 drop in the conjunctival sac of the affected eye(s) once daily, in the morning or evening. Administer at the same time each day.
Contraindications
Children under 18 years
Sinus node dysfunction
Asthma
Breastfeeding
Cardiogenic shock
Corneal dystrophy
History of asthma
Pregnancy
Second degree atrioventricular block
Severe allergic rhinitis
Severe chronic obstructive pulmonary disease
Sinoatrial exit block
Sinus bradycardia
Third degree atrioventricular block
Uncontrolled cardiac failure
Precautions and Warnings
Atopy
Females of childbearing potential
Predisposition to iritis
Predisposition to uveitis
Risk factors for cystoid macular oedema
Soft contact lenses
Aphakia
Cardiovascular disorder
Chronic obstructive pulmonary disease
Corneal disorder
Diabetes mellitus
Dry eyes
First degree atrioventricular block
Hyperthyroidism
Hypotension
Ocular inflammation
Pigmentary glaucoma
Pseudoexfoliative glaucoma
Pseudophakia
Severe circulatory insufficiency
Spontaneous hypoglycaemia
Advise diabetic patients that hypoglycaemic symptoms may be reduced/altered
May mask symptoms of hyperthyroidism
Advise patient blurred vision may affect ability to drive/operate machinery
Contains polyoxyethylene hydrogenated castor oil; may cause skin reactions
Some formulations contain benzalkonium chloride
Some formulations contain propylene glycol
Avoid contact of product with skin
In combined therapy, administer eye products at least five minutes apart
To reduce systemic absorption compress lacrimal sac during administration
Monitor patients with cardiovascular disease
Advise patient of possible change in eye colour
Beta blockers may reduce the response to adrenaline in anaphylaxis
May cause eyelash changes
May cause periorbital/eyelid skin darkening
Systemic absorption & adverse effects of systemic beta blockers may occur
Female: Ensure adequate contraception during treatment
Advise patient to avoid touching the eye/other surfaces with container tip
Remove contact lenses before use and re-insert 15 minutes after use
Pregnancy and Lactation
Pregnancy
Timolol and travoprost eye drops are contraindicated during pregnancy.
The manufacturer does not recommend using timolol and travoprost eye drops during pregnancy. At the time of writing there is limited published information regarding the use of timolol and travoprost eye drops during pregnancy. Potential risks are unknown, however there is a risk of intrauterine growth retardation and signs and symptoms of beta blockade have been observed when beta blockers are administered orally.
Lactation
Timolol and travoprost eye drops are contraindicated during breastfeeding.
The manufacturer does not recommend breastfeeding whilst using timolol and travoprost eye drops. Animal data reports presence of travoprost in the breast milk however presence in human breast milk is unknown. Whilst available data indicates timolol is present in human breast milk, the quantity in the eye drops is not considered to be sufficient to cause adverse effects in the breastfed infant. Effects on exposed infants are unknown.
Side Effects
Abdominal pain
Alopecia
Angioedema
Anterior chamber inflammation
Arrhythmias
Asthenia
Asthenopia
Asthma
Atrioventricular block
Blepharitis
Blurred vision
Bradycardia
Bronchospasm
Cardiac arrest
Cardiac failure
Cerebral ischaemia
Cerebrovascular accident
Changes of blood pressure
Chest pain
Choroidal detachment (following filtration surgery)
Chromaturia
Cold extremities
Congestive cardiac failure
Conjunctival follicles
Conjunctival haemorrhage
Conjunctival oedema
Conjunctivitis
Contact dermatitis
Corneal disorders
Corneal erosion
Cough
Decreased corneal sensitivity
Depression
Diarrhoea
Diplopia
Dizziness
Dry eyes
Dry mouth
Dysgeusia
Dyspepsia
Dyspnoea
Extremity pain
Eyelash growth
Eyelid erythema
Eyelid oedema
Fatigue
Hair growth abnormal
Headache
Hypersensitivity reactions including anaphylaxis
Hypoglycaemia
Increase in serum ALT/AST
Increased iris pigmentation
Increased lacrimation
Insomnia
Iritis
Irregular pulse
Keratitis
Lid margin crusting
Macular oedema
Meibomianitis
Memory loss
Myalgia
Myasthenia gravis-like syndrome
Nasal discomfort
Nausea
Nervousness
Nightmares
Ocular allergy
Ocular hyperaemia
Ocular irritation
Ocular pain
Ocular pruritus
Oedema
Oropharyngeal pain
Palpitations
Paraesthesia
Periorbital oedema
Periorbital skin pigmentation
Photophobia
Postnasal drip
Pruritus
Psoriasis
Ptosis
Punctate keratitis
Rash
Raynaud's syndrome
Reduced libido
Reduced visual acuity
Sexual dysfunction
Skin discolouration
Syncope
Tachycardia
Thirst
Throat irritation
Urticaria
Uveitis
Visual disturbances
Vomiting
Overdosage
It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.
The following number will direct the caller to the relevant local centre (0844) 892 0111
Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( www.toxbase.org ) or if this is unavailable at the backup site ( www.toxbasebackup.org ).
Further Information
Last Full Review Date: October 2021
Reference Sources
Summary of Product Characteristics: DuoTrav eye drops solution. Novartis Pharmaceuticals UK Ltd. Revised November 2020.
Summary of Product Characteristics: Travoprost/Timolol 40micrograms/ml + 5mg/mg eye drops solution. Aspire Pharma Ltd. Revised January 2020.
Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content
FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.